Literature DB >> 20814825

Neurocognitive functioning in school-aged cystinosis patients.

M T P Besouw1, G M Hulstijn-Dirkmaat, R E A van der Rijken, E A M Cornelissen, C M van Dael, J Vande Walle, M R Lilien, E N Levtchenko.   

Abstract

INTRODUCTION: Cystinosis is an autosomal recessive disorder leading to intralysosomal cystine accumulation in various tissues. It causes renal Fanconi syndrome and end stage renal failure around the age of 10 years if not treated with cysteamine. Children with cystinosis seem to have a normal intelligence but frequently show learning difficulties. These problems may be due to specific neurocognitive deficits rather than impaired renal function. Whether cysteamine treatment can improve cognitive functioning of cystinosis patients is thus far unknown. We aim to analyze neurocognitive functioning of school-aged cystinosis patients treated with cysteamine in order to identify specific deficits that can lead to learning difficulties. PATIENTS AND METHODS: Fourteen Dutch and Belgian school-aged cystinosis patients were included. Glomerular filtration rate was estimated using the Schwartz formula. Children were tested for general intelligence, visual-motor integration, inhibition, interference, sustained attention, accuracy, planning, visual memory, processing speed, motor planning, fluency and speed, and behavioural and emotional functioning using standardized methods.
RESULTS: Glomerular filtration rate ranged from 22 to 120 ml min(-1) 1.73 m(-2). Median full-scale intelligence was below the average of a normal population (87, range 60-132), with a discrepancy between verbal (median 95, range 60-125) and performance (median 87, range 65-130) intelligence. Over 50% of the patients scored poorly on visual-motor integration, sustained attention, visual memory, planning, or motor speed. The other tested areas showed no differences between patients' and normal values.
CONCLUSION: Neurocognitive diagnostics are indicated in cystinosis patients. Early recognition of specific deficits and supervision from special education services might reduce learning difficulties and improve school careers.

Entities:  

Mesh:

Year:  2010        PMID: 20814825      PMCID: PMC2992654          DOI: 10.1007/s10545-010-9182-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


Introduction

Cystinosis is a rare autosomal recessive disorder caused by mutations in the CTNS gene, encoding the lysosomal cystine carrier cystinosin. This results in intralysosomal accumulation of the amino acid cystine (Town et al. 1998). The most frequent and severe infantile form has an incidence of 1 case in every 100,000 to 200,000 live births. Children present with renal Fanconi syndrome, mostly during the first year of life. This generalized proximal tubular damage progresses towards end stage renal disease around the age of 10 years. Extra-renal organs are also affected, including eyes, endocrine organs, muscles, and central nervous system. Cystinosis is treated by administration of the cystine-depleting agent cysteamine, which slows down the progression of renal failure and protects extra-renal organs (Gahl et al. 2002). Previously it was believed that since children with cystinosis have a normal intelligence, no learning difficulties should be expected. Moreover, poor school results were often explained by renal disease or seen as a consequence of a chronic illness and its treatment. In 1988, however, it was demonstrated that cystinosis patients have neurocognitive impairments that cannot be attributed to their decreased renal function (Trauner et al. 1988). Despite a normal intelligence, deficits in visual information processing and tactile recognition processing have been reported. As a result, poor school performances, in particular for spelling and arithmetic, have been found (Ballantyne et al. 1997; Colah and Trauner 1997; Spilkin et al. 2007; Williams et al. 1994; Wolff et al. 1982). The aim of this study was to analyze neurocognitive functioning in Dutch and Belgian school-aged cystinosis patients treated with cysteamine starting from an early age in order to identify specific deficits that might lead to learning difficulties and to evaluate the influence of cysteamine treatment. Furthermore, we analyzed the effect of different CTNS mutations on neurocognitive functioning.

Patients and methods

Fourteen school-aged cystinosis patients (age 6–17 years), treated in three Dutch and two Belgian hospitals, were included. Cystinosis was diagnosed at a mean age of 1 year and 10 months, and cysteamine treatment was started immediately thereafter and monitored by measuring white blood cell (WBC) cystine levels every 2–4 months. The diagnosis was confirmed by mutational analysis of the CTNS gene in 13/14 patients. “Whole life” mean WBC cystine levels were calculated from all measurements after the onset of cysteamine treatment. The glomerular filtration rate (GFR) at the moment of testing was estimated using the Schwartz formula (Schwartz et al. 2009). Patients were scheduled for neurocognitive assessment after written informed consent was obtained from parent(s) and patients ≥12 years of age. A standard test battery was completed by all patients. These tests were administered by a trained psychology assistant, who was supervised by a research psychologist. The study was approved by the institutional review board of the Radboud University Medical Centre.

General intelligence

WISC-III

The Wechsler Intelligence Scale for Children, 3rd edition (WISC-III) is a standardized method to test the intelligence quotient (IQ) in children 6–16 years of age (Kort et al. 2002; Wechsler 1991). Patient 8 (17.4 years of age) completed the Wechsler Adult Intelligence Scale (WAIS). Three general measures were derived: full-scale IQ, verbal IQ, and performance IQ.

Neurocognitive function

VMI

The Developmental Test of Visual-Motor Integration (VMI) measures visual-motor integration skills, indicated by the ability to copy increasingly complex geometric forms (Beery 1997).

Stroop Color-Word Interference Test

The Stroop Color-Word Interference Test measures inhibition and interference (e.g., the ability to suppress a habitual response in support of an unusual one) (Hammes 1978). It is divided into word reading (reading color names printed in black) and color naming (naming the print colors of colored bars and naming the print colors of color names when both are not the same). The latter measures the ability to say the print color while suppressing the response to say the color name, which is an interference test. Although this test was originally developed for adults, standardized age norms (7–12 years) for the Dutch population were available and used. The test was not performed in patient 2, since she was <7 years of age and in patients 4 and 8, since they were >12 years of age.

Bourdon-Vos Test

The Bourdon-Vos Test measures sustained attention and accuracy (Vos 1998). Children had to cross out all groups of four dots on a page filled with groups of three, four, and five dots. Scores for both speed and accuracy were normed and evaluated. Patient 13 was too tired to complete the test.

Rey-Osterrieth Complex Figure

Rey’s figure was administered to measure planning (organization) and visual memory (Bernstein and Waber 1996). Children had to copy a complex figure and draw it from memory immediately thereafter (immediate recall) and after a delay of 20 min (delayed recall). Since the test has a norm only for children up to 14 years of age, it was not performed in patients 4 and 8.

Computerized drawing task

A computerized drawing task was administered to evaluate processing speed, motor planning, motor fluency, and motor speed (Schoemaker et al. 1994). Drawing movements were digitally recorded by a digitizing tablet and a wireless electronic pen. Processing speed was indicated by mean reaction time, motor planning by mean duration of pauses between small and large elements, motor fluency by mean number of velocity peaks, and motor speed by mean drawing speed (cm/s).

Behavioral and emotional functioning

CBCL

The Child Behavior Checklist (CBCL) is used to recognize problems of behavioral and emotional functioning (Achenbach 1991). Three parallel versions of the Dutch CBCL were administered: a parent’s version, a patient’s version for children ≥12 years of age, and a teacher’s version (Verhulst et al. 1996, 1997a, b). Scores indicating internalizing, externalizing, and total problems were derived.

Statistical analysis

Correlations between full-scale, verbal, and performance IQ and GFR and between full-scale, verbal, and performance IQ and “whole life” WBC cystine levels were estimated using the Spearman rank correlation method. The general intelligence measures of patients having a homozygous 57 kb deletion of the CTNS gene were compared with those of patients with other mutations using the Mann-Whitney U tests. Values were considered statistically significant at P < 0.05.

Results

Data on GFR, WBC cystine levels, CTNS gene mutations, and educational levels of the parents are shown in Table 1. Eight patients were homozygous for the large 57 kb deletion in the CTNS gene, and five patients were heterozygous and had the 57 kb deletion combined with another mutation; DNA analysis was not performed in patient 13. GFR ranged from 22 to 120 (normal ≥90) ml min−1 1.73 m−2, seven patients had a decreased GFR of <90 ml min−1 1.73 m−2, and patient 4 had a functioning renal graft. Mean WBC cystine levels were within the range of healthy carriers (0.26–0.86 nmol half-cystine/mg protein) in 5/14 patients, indicating adequate cysteamine treatment (Table 1). Results of the neurocognitive tests are shown in Table 2. Scores were defined as average, poor, or low according to the instructions in the test manuals. In all tests except for Rey’s figure, a score of 1 standard deviation (SD) or more above or below the average was considered to be significant. In Rey’s figure, scores were qualified as poor if below or equal to the 10th percentile and good if above or equal to the 90th percentile. The WISC-III, WAIS, and VMI have an average score of 100, with an SD of 15.
Table 1

Clinical data on the patients and educational levels of the parents

PatientAge (years)SexAge at onset of cysteamine therapy (years)DNA analysis of CTNS geneRenal statusGFR (ml min−1 1.73 m−2)Mean (SD) cystine levelsa (nmol half-cystine/mg protein)Educational background fatherEducational background mother
0110.0F1.2hom 57 kb delNK220.98 (0.46)UU
026.3F1.357 kb del/c.del18_21GACTNK863.10 (1.36)VV
0311.1F1.10hom 57 kb delNK480.74 (0.64)VLS
0415.5F1.8hom 57 kb delTx720.92 (0.52)HVHV
0510.7M9.057 kb del/c.198_218del21NK1131.10 (0.36)VHS
068.4M1.3hom 57 kb delNK840.86 (0.54)VHS
079.2M0.9hom 57 kb delNK1000.96 (0.52)VLS
0817.4M0.6hom 57 kb delNK570.84 (0.40)HVV
0911.8F1.457 kb del/c.665 A>GNK1200.64 (0.34)VV
1011.8F1.457 kb del/c.665 A>GNK1200.60 (0.34)VV
1111.3M2.857 kb del/c.926dupNK892.03 (1.28)VHV
127.4M0.10hom 57 kb delNK1124.75 (2.62)UU
138.1M1.6Not doneNK1181.56 (0.68)VLS
148.6M0.10hom 57 kb delNK1030.96 (0.74)LVLS

NK Native kidney, Tx renal transplantation, V vocational education, LV lower vocational education, HV higher vocational education, LS lower secondary education, HS higher secondary education, U university education

aNormal values for healthy carriers: 0.26–0.86 nmol half-cystine/mg protein

Table 2

Test results

PatientWISC/WAISVMIStroopa Bourdona Rey’s figurea Experimental drawing taska
VIQPIQFIQSustained attentionAccuracyPlanningVisual memoryProcessing speedMotor planningMotor fluencyMotor speed
0196758487=====+==
0212513013294NDb =+====
031118810073+++===
0411710111197NDc =+NDc NDc ====
05869488110=====+=
0679807783========
0796788694+====
0881d 75d 77d 77NDc +NDc NDc ==+=
0960656081=+===
1064726574++==
111059510090=+==+
121109510393NDe NDe ===++
13941059984===
1490858665+==

VIQ Verbal intelligence quotient, PIQ performance intelligence quotient, FIQ full-scale intelligence quotient, VMI visual-motor integration, ND not determined

aCognitive function test results: = average performance (<1 SD below or above average, Rey’s figure 10th-90th percentile), + good performance (≥1 SD above average, Rey’s figure ≥90th percentile), − poor performance (≥1 SD below average, Rey’s figure ≤10th percentile)

bTest not performed because patient was below 7 years of age

cTest not performed because patient was over 12 years of age (Stroop), over 14 years of age (Rey’s figure)

dTested with Wechsler Adult Intelligence Scale (WAIS)

eTest not performed because patient was too tired

Clinical data on the patients and educational levels of the parents NK Native kidney, Tx renal transplantation, V vocational education, LV lower vocational education, HV higher vocational education, LS lower secondary education, HS higher secondary education, U university education aNormal values for healthy carriers: 0.26–0.86 nmol half-cystine/mg protein Test results VIQ Verbal intelligence quotient, PIQ performance intelligence quotient, FIQ full-scale intelligence quotient, VMI visual-motor integration, ND not determined aCognitive function test results: = average performance (<1 SD below or above average, Rey’s figure 10th-90th percentile), + good performance (≥1 SD above average, Rey’s figure ≥90th percentile), − poor performance (≥1 SD below average, Rey’s figure ≤10th percentile) bTest not performed because patient was below 7 years of age cTest not performed because patient was over 12 years of age (Stroop), over 14 years of age (Rey’s figure) dTested with Wechsler Adult Intelligence Scale (WAIS) eTest not performed because patient was too tired Median full-scale IQ was 87 (range 60–132), median verbal IQ 87 (range 60–125), and median performance IQ 95 (range 65–130). Five patients (36%) scored ≥1 SD below the average for full-scale IQ. In five patients (36%), the verbal IQ was ≥1 SD higher than the performance IQ, none of the patients had a significantly better performance IQ compared to the verbal IQ.

Neurocognitive functions

All 14 children completed the VMI. Seven children (50%) had a poor performance (≤85 points), and none had a good performance (≥115 points) on this test. The Stroop Color-Word Interference Test was performed in 11/14 patients and showed no abnormalities: 5 children (45%) had an average performance, 3 children (27%) had a poor performance, and 3 children (27%) had a good performance. The Bourdon-Vos Test was performed in 13/14 patients. Only four patients (31%) showed a normal sustained attention, while the other nine patients (69%) showed a delayed sustained attention. There were no evident problems in accuracy: six children (46%) had a good performance, five children (38%) had a poor performance. The Rey-Osterrieth Complex Figure was completed by 12/14 children. Four patients (33%) had a score of poor on planning (organization), only one patient (8%) had a score of good on planning items. Three patients (25%) had a score of poor on visual memory, none had a score of good on this item. The computerized drawing task was completed by all 14 children. Two patients (14%) had a good score on processing speed, and four patients (29%) had a poor score on this item. One patient (7%) had a good score on motor planning, whereas eight patients (57%) had a poor score on this measure. Motor fluency and motor speed showed no evident problems: three patients (21%) showed a good score and two patients (14%) showed a poor score on motor fluency, while two patients (14%) showed a good score and three patients (21%) showed a poor score on motor speed. Teachers reported poor school performances in two or more areas in seven patients (50%, data not shown). The reported problem areas included arithmetic, spelling, reading comprehension, and knowledge of the world. All seven of these patients (patients 01, 03, 07, 08, 09, 10, and 14) had a risk profile for neurocognitive dysfunction, e.g., they showed a low general intelligence level or a discrepancy between verbal and performance IQ and/or a poor performance on neurocognitive tasks. No significant behavioral or emotional problems were reported by parents or patients. We found no significant correlation between full-scale, verbal, and performance IQ and GFR. Unexpectedly, a significant positive correlation was found between mean “whole-life” WBC cystine levels and full-scale IQ (R = 0.68, P = 0.007), verbal IQ (R = 0.57, P = 0.033), and performance IQ (R = 0.73, P = 0.003). Full-scale, verbal, and performance IQ were not different between patients having the homozygous 57 kb deletion and patients with other mutations.

Discussion

This study aimed at examining neurocognitive functioning in school-aged cystinosis patients treated with cysteamine starting at an early age in order to find evidence for clinically observed learning difficulties in this patient group. We found a poorer performance on visual-motor integration (VMI), sustained attention (Bourdon-Vos Test), visual memory (Rey’s figure), planning (Rey’s figure, drawing task), and motor speed (drawing task). The finding of a full-scale IQ just below the average with a relative good verbal IQ and poor performance IQ combined with poor executive functions is in line with the results of other international studies on neurocognitive functioning in children with cystinosis (Ballantyne et al. 1997; Colah and Trauner 1997; Spilkin et al. 2007, 2009; Ulmer et al. 2009; Williams et al. 1994; Wolff et al. 1982). Interestingly, teachers reported more school problems than parents and patients ≥12 years (CBCL). It should be noted however that scores on the CBCL are slightly distorted in pediatric populations (Perrin et al. 1991). This is due to the fact that children suffering from a somatic disorder show an increased risk for overall adjustment problems, internalizing and (to a lesser extent) externalizing symptoms. Therefore, they are more likely to show higher scores on the scales of somatic complaints and internalizing problems when compared to their healthy peers (Lavigne and Faier-Routman 1992). It is known that patients over 12 years of age do not seem to recognize their emotional and learning difficulties (Delgado et al. 2005; Gipson et al. 2004), and it might be suggested that parents do not expect their children to have major school problems, since they seem to have a normal intelligence and in particular normal or even above normal verbal levels. A study using the CBCL conducted in 2005 on behavioral problems in children with cystinosis revealed more social problems in cystinosis patients compared to patients with another chronic disease (cystic fibrosis) and compared to healthy control subjects. However, in that study only the patients and their parents, and not the teachers, completed the checklists (Delgado et al. 2005). In our study, such behavioral problems were not reported. A limitation of this study is the small study population, since cystinosis is a very rare disorder. We also found a broad heterogeneity in terms of general intelligence. On the other hand, the strength of this work lays in the broad pallet of standardized tests, which were adequately administered by a trained team of psychologists.

Pathogenesis of neurocognitive disturbances in cystinosis

The pathogenesis of brain involvement in cystinosis remains unclear. Thus far, three hypotheses have been postulated. These include progressive accumulation of cystine in brain cells (in particular oligodendrocytes), progressive development of intracranial microvascular disease, and alterations of the blood-brain barrier leading to cystine deposits within cerebral pericytes, thus making them unable to prevent circulating toxins from entering the central nervous system (Vogel et al. 1990). A study performed on ctns -/- knockout mice showed spatial short-term memory impairments, comparable to the cognitive anomalies found in cystinosis patients. The highest cystine levels were found in the hippocampus, cerebellum, and brainstem, respectively (Maurice et al. 2009). In human cystinosis patients, cystine accumulates in all parts of the brain, especially in the basal ganglia (Jonas et al. 1987). Whether cysteamine therapy is able to influence learning difficulties remains unclear. Our study failed to demonstrate a positive effect of cysteamine therapy, evaluated by “whole-life” WBC cystine levels, on neurocognitive functioning. In line with our results, it should be noted that the study by Wolff et al. conducted on patients not treated with cysteamine showed a similar pattern of normal general intelligence with relatively poor scores for performance IQ and relative good scores for verbal IQ (Wolff et al. 1982). Interestingly, we found a positive correlation between WBC cystine levels and full-scale, verbal, and performance IQ results. This unexpected observation might be due to unknown side effects of cysteamine on brain function. Cysteamine is suggested to cross the blood-brain barrier as mixed disulfide with cysteine and is reduced in cerebro to free cysteamine. The administration of supraclincal doses of cysteamine (250 mg/kg) to rats showed a remarkable increase in cerebral and cerebellar levels of methionine, and a drop in cerebral levels of cysteine and an anti-oxidant compound, S-(2-aminoethyl)-L-cysteine ketimine decarboxylated dimer (AECK-DD), probably due to the oxidative effect of cysteamine (Pinto et al. 2009). It cannot be ruled out that the administration of high cysteamine doses might have a detrimental effect on the brain. Studies of cysteamine metabolites in the spinal fluid of cystinosis patients might help to clarify pathways involved in cerebral cysteamine metabolism in humans and to identify eventual markers of cysteamine-induced damage. Unfortunately, we could not determine “whole-life” cysteamine dose in our patients because it was not always correctly noted in the patient’s records, and we had no information about compliance. In an earlier study, a negative association was found between the variance in cystine levels and performance IQ (Bava et al. 2010); these findings should be further examined in larger patient populations and in ctns -/- mice treated with cysteamine. In our study, patients with the homozygous 57 kb deletion had a general intelligence comparable to those with heterozygous mutations. This suggests that the absence of the CARKL gene, which is another gene removed in patients with homozygous 57 kb deletion (Wamelink et al. 2008), does not contribute to the cerebral dysfunction of cystinosis patients.

Conclusion

Neurocognitive diagnostics aimed at visual-motor integration, visual memory, planning, sustained attention, and motor speed are indicated in all cystinosis patients from the age of 7–8 years. Deficits in these fields can lead to learning difficulties in reading, spelling, and arithmetic. For instance, poor visual motor integration, motor speed, and sustained attention may prevent the child from recognizing letter forms, recalling and writing them, and from meeting the time constraints often involved in school assignments. Early neuropsychological diagnostics can contribute to early recognition from special education services, which might reduce the development of these learning problems and result into targeted remedial teaching. Parents and teachers should be informed that possible deficits or “minor symptoms” might not be attributed to the general effects of having a chronic disease. Further research on the etiology of specific deficits of neurocognitive functioning in school-aged cystinosis patients is recommended.
  19 in total

1.  Central nervous system involvement in nephropathic cystinosis.

Authors:  D G Vogel; M H Malekzadeh; M E Cornford; J A Schneider; W D Shields; H V Vinters
Journal:  J Neuropathol Exp Neurol       Date:  1990-11       Impact factor: 3.685

Review 2.  Cystinosis.

Authors:  William A Gahl; Jess G Thoene; Jerry A Schneider
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

3.  Tactile recognition in infantile nephropathic cystinosis.

Authors:  S Colah; D A Trauner
Journal:  Dev Med Child Neurol       Date:  1997-06       Impact factor: 5.449

4.  Intellectual and motor performance, quality of life and psychosocial adjustment in children with cystinosis.

Authors:  Francis F Ulmer; Markus A Landolt; Russia Ha Vinh; Thierry A G M Huisman; Thomas J Neuhaus; Bea Latal; Guido F Laube
Journal:  Pediatr Nephrol       Date:  2009-03-18       Impact factor: 3.714

5.  Global intellectual deficits in cystinosis.

Authors:  B L Williams; J A Schneider; D A Trauner
Journal:  Am J Med Genet       Date:  1994-01-01

6.  Nephropathic cystinosis with central nervous system involvement.

Authors:  A J Jonas; S B Conley; R Marshall; R A Johnson; M Marks; H Rosenberg
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

7.  Developmental changes in cerebral white matter microstructure in a disorder of lysosomal storage.

Authors:  Sunita Bava; Rebecca J Theilmann; Miriam Sach; Susanne J May; Lawrence R Frank; John R Hesselink; Duc Vu; Doris A Trauner
Journal:  Cortex       Date:  2009-04-05       Impact factor: 4.027

8.  Psychosocial and intellectual development in 12 patients with infantile nephropathic cystinosis.

Authors:  G Wolff; J H Ehrich; G Offner; J Brodehl
Journal:  Acta Paediatr Scand       Date:  1982-11

9.  Cautions in using the Child Behavior Checklist: observations based on research about children with a chronic illness.

Authors:  E C Perrin; R E Stein; D Drotar
Journal:  J Pediatr Psychol       Date:  1991-08

10.  Sedoheptulokinase deficiency due to a 57-kb deletion in cystinosis patients causes urinary accumulation of sedoheptulose: elucidation of the CARKL gene.

Authors:  Mirjam M C Wamelink; Eduard A Struys; Erwin E W Jansen; Elena N Levtchenko; Fokje S M Zijlstra; Udo Engelke; Henk J Blom; Cornelis Jakobs; Ron A Wevers
Journal:  Hum Mutat       Date:  2008-04       Impact factor: 4.878

View more
  9 in total

Review 1.  [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].

Authors:  Jessica Kaufeld; Lutz T Weber; Christine Kurschat; Sima Canaan-Kuehl; Eva Brand; Jun Oh; Lars Pape
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

2.  Cognition in nephropathic cystinosis: pattern of expression in heterozygous carriers.

Authors:  Stephen Niemiec; Angela Ballantyne; Doris A Trauner
Journal:  Am J Med Genet A       Date:  2012-07-11       Impact factor: 2.802

3.  Executive function in nephropathic cystinosis.

Authors:  Angela O Ballantyne; Amy M Spilkin; Doris A Trauner
Journal:  Cogn Behav Neurol       Date:  2013-03       Impact factor: 1.600

4.  Management dilemmas in pediatric nephrology: Cystinosis.

Authors:  Martine T P Besouw; Maria Van Dyck; David Cassiman; Kathleen J Claes; Elena N Levtchenko
Journal:  Pediatr Nephrol       Date:  2015-05-09       Impact factor: 3.714

Review 5.  Cystinosis: a review.

Authors:  Mohamed A Elmonem; Koenraad R Veys; Neveen A Soliman; Maria van Dyck; Lambertus P van den Heuvel; Elena Levtchenko
Journal:  Orphanet J Rare Dis       Date:  2016-04-22       Impact factor: 4.123

6.  Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease.

Authors:  Sören Bäumner; Lutz T Weber
Journal:  Front Pediatr       Date:  2018-03-14       Impact factor: 3.418

7.  Neuropsychological and neuroanatomical phenotype in 17 patients with cystinosis.

Authors:  Aurore Curie; Nathalie Touil; Ségolène Gaillard; Damien Galanaud; Nicolas Leboucq; Georges Deschênes; Denis Morin; Fanny Abad; Jacques Luauté; Eurielle Bodenan; Laurent Roche; Cécile Acquaviva; Christine Vianey-Saban; Pierre Cochat; François Cotton; Aurélia Bertholet-Thomas
Journal:  Orphanet J Rare Dis       Date:  2020-02-26       Impact factor: 4.123

8.  Assessing the integrity of auditory processing and sensory memory in adults with cystinosis (CTNS gene mutations).

Authors:  Ana A Francisco; Alaina S Berruti; Frederick J Kaskel; John J Foxe; Sophie Molholm
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

Review 9.  Central Nervous System Complications in Cystinosis: The Role of Neuroimaging.

Authors:  Aude Servais; Jennifer Boisgontier; Ana Saitovitch; Aurélie Hummel; Nathalie Boddaert
Journal:  Cells       Date:  2022-02-15       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.